Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Conditions

Multiple Myeloma 11Lymphoma 11Precursor Cell Lymphoblastic Leukemia-Lymphoma 10Neoplasm Metastasis 9Leukemia 9Neoplasms 8Myelodysplastic Syndromes 8Hodgkin Disease 8Carcinoma, Non-Small-Cell Lung 8Breast Neoplasms 8Lymphoma, Non-Hodgkin 7Leukemia, Myeloid, Acute 7Carcinoma, Renal Cell 7Prostatic Neoplasms 6Melanoma 6Leukemia, Myelogenous, Chronic, BCR-ABL Positive 6Recurrence 5Leukemia, Lymphocytic, Chronic, B-Cell 5Hematologic Neoplasms 5Graft vs Host Disease 5Advanced Cancer 5Unspecified Adult Solid Tumor, Protocol Specific 4Primary Myelofibrosis 4Pancreatic Neoplasms 4Neoplasms, Plasma Cell 4Myeloproliferative Disorders 4Lung Neoplasms 4Leukemia, Myelomonocytic, Chronic 4Leukemia, Myeloid, Chronic-Phase 4Glioblastoma 4

Interventions

pembrolizumab 1Sirolimus 1Nivolumab 1Ipilimumab 1Docetaxel 1Albumin-Bound Paclitaxel 1ADI PEG20 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × Advanced Solid Cancers × Sirolimus × Clear all
NCT00337376 2014-01-14

A Study of the mTOR Inhibitor Rapamycin (Rapamune, Sirolimus) in Combination With Abraxane in Advanced Solid Cancers

Yale University

Phase 1 Terminated
23 enrolled

Advanced Solid Cancers

Data powered by HemOnc (CC BY 4.0) Colophon âš¡